NCT01404182 - Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons | Biotech Hunter

Enrollment

121

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Influenza

Interventions

BIOLOGICAL

Vaccination with Fluval AB influenza vaccine

Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.

Trial Locations (2)

H-2097

Family Doctor's Office, Pilisvörösvár

H-8200

Fourmed Gyogyhaz Kft., Veszprém